Medizinische Universitaet Innsbruck
- Address
- lock Available on a paid plan
Psychiatry and Psychology – Mental Disorders
The research unit of Medizinische Universitaet Innsbruck advances mental health science, focusing on innovative therapies for severe psychiatric conditions.
- Schizophrenia
- Bipolar disorder
- Major depressive disorder
- Cognitive impairment in schizophrenia
- Early psychosis
- Treatment‑resistant depression
Current trials assess novel antipsychotics and cognitive‑enhancing agents to improve functional recovery and quality of life.
Nervous System Diseases
Investigations target disorders of the central and peripheral nervous system, seeking disease‑modifying strategies for neurodegenerative and neuroinflammatory illnesses.
- Alzheimer’s disease
- Parkinson’s disease
- Multiple sclerosis
- Huntington’s disease
- Amyotrophic lateral sclerosis
- Progressive supranuclear palsy
Studies evaluate biomarkers and emerging biologics to slow progression and preserve neurological function.
Cardiovascular Diseases
The site conducts research on cardiovascular health, aiming to reduce morbidity through novel therapeutic and diagnostic approaches.
- Atherosclerotic cardiovascular disease
- Hypertension
- Heart failure with preserved ejection fraction
- Transthyretin amyloid cardiomyopathy
- Peripheral arterial disease
- Acute coronary syndrome
Projects include precision‑medicine trials of antiplatelet regimens and gene‑based risk stratification tools.
Immune System Diseases and Autoimmunity
Researchers explore immune‑mediated disorders to develop targeted interventions that restore immune balance.
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Sjögren’s syndrome
- Vasculitis (ANCA‑associated)
- Immunoglobulin A nephropathy
- Hypereosinophilic syndrome
Clinical programs test complement inhibitors, cytokine blockers, and novel small molecules for disease control.
Oncology – Neoplasms
The department participates in cutting‑edge cancer research, focusing on targeted and immunotherapies across solid and hematologic malignancies.
- Breast cancer (HR+/HER2‑, HER2+)
- Non‑small cell lung cancer
- Ovarian and fallopian tube cancer
- Multiple myeloma
- Lymphomas (follicular, marginal zone, DLBCL)
- Metastatic prostate cancer
Trials evaluate antibody‑drug conjugates, checkpoint inhibitors, and combination regimens to improve survival outcomes.
Respiratory and Pulmonary Diseases
Studies address lung and airway disorders, seeking better management of chronic and acute respiratory conditions.
- Chronic obstructive pulmonary disease
- Asthma
- Pulmonary arterial hypertension
- Interstitial lung disease associated with hypertension
- Small cell lung cancer
- Bronchiectasis
Research includes inhaled therapies, novel vasodilators, and biomarker‑driven patient stratification.
Digestive System Diseases
The team investigates gastrointestinal disorders, aiming to enhance diagnostic precision and therapeutic effectiveness.
- Crohn’s disease
- Ulcerative colitis
- Celiac disease
- Chronic hepatitis D infection
- Alcohol‑associated hepatitis
- Non‑alcoholic steatohepatitis (NASH)
Ongoing work evaluates biologics, small‑molecule inhibitors, and lifestyle interventions for disease remission.
Kidney and Urinary Tract Disorders
Research focuses on renal and urogenital diseases, targeting improved outcomes for chronic and acute kidney conditions.
- Autosomal dominant polycystic kidney disease
- IgA nephropathy
- Diabetic kidney disease
- Delayed graft function after transplantation
- Acute kidney injury related to contrast media
- Female urogenital disorders
Trials assess vasopressin‑2 receptor antagonists, contrast‑sparing strategies, and novel immunosuppressive protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 24 therapeutic areas and 15 of 564 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 539 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 103 by active trials.
- 1AstraZeneca AB10active
lock +102 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB23trials
lock +60 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinische Universitaet Innsbruck
lock Showing 1 of 354 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 564 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 33 | Unknown | 2015-05-05 | 2026-06-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.